Melatonin as an immunomodulator in CD19-targeting CAR-T cell therapy: managing cytokine release syndrome
Abstract Background Chimeric antigen receptor CAR-T cell therapies have ushered in a new era of treatment for specific blood cancers, offering unparalleled efficacy in cases of treatment resistance or relapse. However, the emergence of cytokine release syndrome (CRS) as a side effect poses a challen...
Hauptverfasser: | , , , , , , , , |
---|---|
Format: | Artikel |
Sprache: | English |
Veröffentlicht: |
BMC
2024-01-01
|
Schriftenreihe: | Journal of Translational Medicine |
Schlagworte: | |
Online Zugang: | https://doi.org/10.1186/s12967-023-04779-z |